India's COVID-19 Vaccine Found Effective Against Brazil and UK Variants
Scientists at the Indian Council of Medical Research-National Institute of Virology confirmed on April 30, 2021, they have found that the Covaxin COVID-19 vaccine is effective against the Brazil variant, B.1.128.2.
Published as a bioRxiv preprint, this new study shows that the two-dose regimen significantly boosted IgG antibody titer and neutralizing efficacy against the Brazil variant and D614G variant as compared to that seen with natural infection.
This study also demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.22.214.171.124 variant compared to prototype D614G variant with sera of vaccine recipients and natural infection, respectively.
A recent study found Covaxin effective against the UK variant and the Indian (double mutant) variant B.1.617.
Covaxin (BBV152) is an inactivated COVID-19 vaccine that uses adjuvant Alhydroxiquim-II to boost immune response longer-lasting immunity and was developed by Bharat Biotech in 2020. It is the first COVID-19 vaccine developed completely in India.
Ocugen, Inc., a Pennsylvania-based company, announced on February 2, 2021, it entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin in the United States market.